About CorneaGen
CorneaGen is a company based in Seattle (United States) founded in 2017. CorneaGen has raised $42 million across 3 funding rounds from investors including Petrichor and Flying L Partners. The company has 205 employees as of December 31, 2020. CorneaGen has completed 1 acquisition, including KeraLink International. CorneaGen offers products and services including CTAK, EndoSerter-PL, VisionGraft, and Geuder Pre-Loaded Glass Cannula. CorneaGen operates in a competitive market with competitors including Cellusion, EyeGate, CorNeat Vision, Avedro and EyeYon, among others.
- Headquarter Seattle, United States
- Employees 205 as on 31 Dec, 2020
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$42 M (USD)
in 3 rounds
-
Latest Funding Round
$25 M (USD), Debt – Conventional
Oct 07, 2019
-
Investors
Petrichor
& 1 more
-
Employee Count
205
as on Dec 31, 2020
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of CorneaGen
CorneaGen offers a comprehensive portfolio of products and services, including CTAK, EndoSerter-PL, VisionGraft, and Geuder Pre-Loaded Glass Cannula.
Provides laser-cut tissue inlays for enhanced vision in keratoplasty.
Pre-loaded tool for DSEK procedures to improve surgical outcomes.
Offers ready corneal grafts for ocular surgeries to restore sight.
Facilitates DMEK surgery with pre-loaded delivery for precision.
People of CorneaGen
Unlock access to complete
Unlock access to complete
Funding Insights of CorneaGen
CorneaGen has successfully raised a total of $42M across 3 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $25 million completed in October 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in CorneaGen
CorneaGen has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Petrichor and Flying L Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Petrichor is engaged in supporting healthcare innovation through investments.
|
Locked | Locked | Locked | |
|
Flying L Partners is focused on ophthalmic sector investments.
|
Locked | Locked | Locked |
Investor details for CorneaGen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CorneaGen
CorneaGen has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include KeraLink International.
Investment portfolio details for CorneaGen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Foundation focused on developing affordable corneal blindness treatment
|
Locked | Locked | 1962 | Locked |
Complete acquisition details for CorneaGen
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - CorneaGen
Detailed financials for CorneaGen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Corneagen Comparisons
Peer comparison for CorneaGen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of CorneaGen
CorneaGen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Cellusion, EyeGate, CorNeat Vision, Avedro and EyeYon, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
iPS cell-based technology for corneal endothelium regeneration is developed.
|
|
| Locked | Locked | Locked |
Therapeutics and drug delivery systems for eye diseases are developed.
|
|
| Locked | Locked | Locked |
Nanotechnology-based artificial corneal implants are developed for ophthalmic use.
|
|
| Locked | Locked | Locked |
Corneal collagen cross-linking technology is developed for ophthalmic applications.
|
|
| Locked | Locked | Locked |
Ophthalmic devices for corneal edema treatment are developed.
|
Detailed competitors of CorneaGen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Corneagen
Complete news archive for CorneaGen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CorneaGen
CorneaGen was founded in 2017 and raised its 1st funding round 1 year after it was founded.
CorneaGen is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Monty Montoya is the current CEO of CorneaGen.
CorneaGen is a funded company, having raised a total of $42M across 3 funding rounds to date.
As of Dec 31, 2020, the latest employee count at CorneaGen is 205.
CorneaGen was founded in 2017 and is based in Seattle, United States. Operations center on the development of therapeutic devices within the ophthalmology sector, specifically for corneal transplant procedures. Key products include Ampho B, Pre-Loaded Cannula, Cannula, Donor Punch, EndoSerter, and Recipient Trephine. These devices support surgical processes for corneal care and are targeted at medical professionals in the field.
CorneaGen offers CTAK, EndoSerter-PL, VisionGraft, and Geuder Pre-Loaded Glass Cannula.
CorneaGen has made 1 acquisition, including KeraLink International.
CorneaGen has 2 investors. Key investors include Petrichor, and Flying L Partners.